REZULTATI I DISKUSIJAMetodot beshe kompletno validiran vo soglasnost so nasokite naICH (Megjunarodna konferentsija za kharmonizatsija), prekuopredeluvanje na linearnost, pretsiznost, tochnost, limit nadetektsija i kvantifikatsija. Linearnosta na metodot beshe ispitana vo opseg od: 2 - 100 mg mL-1 sildenafil. (Figura 1). Eksperimentalnite podatotsi pokazhaavisoko nivo na linearnost, shto se potvrduva i so vrednosta nakoefitsientot na korelatsija (R2 = 0.9994).Limitot na detektsija (LOD) i kvantifikatsija (LOQ) na metodot beaispitani vo opseg od: 20 - 200 ng mL-1 sildenafil. Dobienitevrednosti se: 0.23 ng i 0.68 ng za LOD i LOQ, soodvetno (9.2 ng mL-1 i 27.2 ng mL-1 za LOD i LOQ, soodvetno, dobieni so injektiranjena 25 mL).Selektivnosta na metodot beshe potvrdena so rezolutsijata dobienapomegju pikot na sildenafil i pikot na tadalafil (Rs = 10, 5)(Figura 2) i karakteristichniot UV-spektar.Fig. 1. Tipichen bazhdaren dijagram za sildenafil, so ravenka naregresija Abs = 27066 conc. + 14033, i R2 = 0,999453PHARMACEUTICAL ANALYSIS / QUALITY ASSURANCE / REGULATORY AFFAIRS poster presentationsFIFTH CONGRESS OF PHARMACY OF MACEDONIA WITH INTERNATIONAL PARTICIPATIONMacedonian Pharmaceutical Bulletin 57 (suppl), 2011Fig. 2. Tipichen khromatogram dobien od meshan standarden rastvor:sildenafil (1), tadalafil (2).Fig. 3. Tipichen khromatogram dobien od sildenafil vo: standardenrastvor (1), proben rastvor (2).Prosechniot analitichki prinos za sildenafil beshe od 99,74% do100,88% shto pokazhuva deka predlozheniot metod e tochen zaopredleuvanje na sildenafil vo farmatsevtski preparti.Predlozheniot metod beshe uspeshno primenet za opredeluvanje nasildenafil vo dozirni farmatsevtski formi (Figura 3).ZAKLUChOTsIRezultatite od studijata za validatsija pokazhuvaat dka pred lo -zheniot analitichki metod e tochen, pretsizen i reprodutsibilen zaana liza na sildenafil vo farmatsevtski preparati. Do pol ni -telno, ovaa analitichka postapka e relativno evtina i ednostavnai e osobeno pogodna za rutinski analizi koga masena spek tro me -tri ja ne e na raspolaganje. Isto taka, vazhno e da se spomne dekana malenata potroshuvachka na organski rastvoruvach znachitelno ginamaluva laboratoriskite troshotsi.LITERATURA1. Vardi M, Nini A (2007). Phosphodiesterase inhibitors for erectile dysfunction inpatients with diabetes mellitus. Cochrane Database Syst Rev (1): CD002187.doi:10.1002/14651858.CD002187.pub3. PMID 17253475.2. Pomeranz HD and Bhavsar AR (2005). Nonarteritic ischemic optic neuropathydeveloping soon after use of sildenafil (Viagra): a report of seven new cases. J.Neuroophthalmol. 25 (1): 9-13. PMID 15756125.3. Webb DJ, Freestone S, Allen MJ, Muirhead GJ. (March 4, 1999). Sildenafil citrateand blood-pressure-lowering drugs: results of drug interaction studies with anorganic nitrate and a calcium antagonist. Am. J. Cardiol. 83 (5A): 21C-28C.doi:10.1016/S0002-9149(99)00044-2. PMID 10078539.4. Francis SH, Morris GZ, Corbin JD. Molecular mechanisms that could contributeto prolonged effectiveness of PDE5 inhibitors to improve erectile function. Int. J.Impot. Res. 2008 Jul-Aug;20(4):333-42. 5. ICH Q2R1: Validation of Analytical Procedures: Text and Methodology,Proceeding of the International Conference on Harmonisation of technicalRequirements for Registration of pharmaceuticals for Human Use, Geneva,Switzerland, 1996.EFFECT OF HYDRODYNAMICS ON THE DIS-SOLUTION TEST OF BCS CLASS II ACTIVECOMPONENT FORMULATED AS SOLIDDOSAGE FORM WITH IMMEDIATE RELEASEIrena Brasnarska, Natasa Karalija, Suzan Memed-Sejfulah, Sanja Simeonovska, Gjorgji Petrusevski,Ema Kikovska-Stojanovska, Biljana Sapkareva,Sonja UgarkovicResearch and Development, ALKALOID AD, Aleksandar Makedonski 12,1000 Skopje, Republic of MacedoniaINTRODUCTIONThe in vitro dissolution test in the last few decades of drug product de-velopment has distinguished as important physicochemical tool forevaluation of the pharmaceutical quality and bioavailability of theproduct. Dissolution method development must be considered as acontinuing process that needs to adapt to changes as the productchanges. Specific drug substance information like: solubility, pKa, sta-bility as a function of pH and BCS classification give directions to theresearch team to develop product specific discriminatory dissolutionmethod. Different rotation speeds, different mediums and differentapparatus must be evaluated to define dissolution method that canprovide appropriate measure of product performance, but also havesufficient discriminatory power to detect changes in the formulation. Film-coated tablets with immediate release and incorporated BCSClass II active component [1] (low solubility, high permeability), pKa ~4.5 were evaluated in this study. The active component has a pH de-pendent solubility and increase of the pH would enhance its solubilityand consequently the dissolution rate, particularly at pH > pKa of thecompound. (Fig.1) Solubility of the active substance was determinedby shake-flask method in three different media. The results were0.00385 mg/ml, 0.0113 mg/ml and 0.143 mg/ml for pH 2.2, pH 4.5 andpH 6.8, respectively. The active component is completely ionized andrapidly dissolved in the intestinal region with an average of pH~6.5. Asa result, phosphate buffer pH 6.8 [2] was chosen as physiologically rel-evant and in accordance with the regulatory requirements.Figure1. Dissolution profiles at different pH media54Makedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKI ANALIZI / OBEZBEDUVANjE KVALITET / REGULATIVA poster prezentatsiiPETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOMETHODS AND MATERIALSThe content of dissolved active substance was quantified using HPLCmethod with UV detection at 246 nm, VWR Hitachi Elite La Chrom.Separation was performed on RP Select B 125 x 4.0mm 5mm column.Dissolution test was performed on Varian VK 7025 Dissolution testerusing Apparatus I (basket) and Apparatus II (paddle). Dissolution profiletime points used were 5, 10, 15, 30 and 45 minutes, and for the disso-lution end point test 30 minutes was chosen. Quantitatively propor-tional film-coated tablets with different dosage strengths produced withthe same manufacturing process were used for experimental purposes.RESULTS AND DISCUSSIONa) Influence of rotation speedThe effect of hydrodynamics on the dissolution rate of the active prin-ciple from the formulation has been evaluated by varying paddle ro-tation speed. The evaluation was performed with dissolution end pointtest with rotations of 50 rpm, 75 rpm and 100 rpm. On 50 rpm conningwas noticed which lead to incomplete release of active ingredientfrom tablets. Additionally, high scattered values at the first time pointwere observed from dissolution profiles at 50 rpm in comparison with75 rpm. (Fig.2)Figure2. Dissolution profile with 75rpm and 50 rpm results per vesselTable1. RSD values at first time point from dissolution profiles with75 rpm and 50 rpmIncreased rotation speed at 75 rpm and 100 rpm gave higher results,potentially as a result from reduced coning, which on the other handgives greater exposure of drug component to the dissolution medium.Useful information about the influence of hydrodynamics was gath-ered when Infinity time point test was performed, with increase ofpaddle speed at 250 rpm for additional 30 minutes. The results wereclose to 100%, and although 100% dissolution is not a regulatory re-quirement the dissolution at the infinity point gave prove that higheragitation increases the dissolution rate.Table2. Dissolution end point test results withdifferent rpm* (after 60 minutes)b) Influence of different type of apparatusAdditionally, Apparatus I (basket) was evaluated at 100 rpm [3]. Al-though the results revealed that the use of baskets increases the dis-solution rate, further experiments demonstrated that baskets havelower discriminatory abilities.Figure3. Dissolution profiles on trials with different polymorphicforms performed with Apparatus (I)-100rpm and Apparatus (II)-75rpmIn general, lower rotation speed demonstrated lack of robustness,while higher rotation speeds showed lack of discriminatory power.CONCLUSIONBased on all experiments performed, a specification dissolutionmethod was established which employs Apparatus II (paddle) [4], 75rpm and buffer pH 6.8 as optimal test conditions for evaluation of thespecific compound. During development of the dissolution methodthe right choice of conditions for performance of the test is of the ut-most importance to reflect the product performance from quality aswell as regulatory aspect.REFERENCES1. FDA, CDER 1995. SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Upand Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro DissolutionTesting, and In Vivo Bioequivalence Documentation2. European Pharmacopoeia 6th Edition 2009 Supplement 6.8. Chapter 5.17.1.Recommendations on dissolution testing Directorate for the Quality of Medicines of theCouncil of Europe: Germany 2009.3. United States Pharmacopoeia, USP 32, National Formulary 27. General Chapter 1092 :The dissolution procedure: Development and Validation; United States PharmacopeialConvention: Rockville, MD, 2009.4. European Pharmacopoeia 6th Edition 2009 General Chapter 2.9.3. Dissolution Testfor Solid Dosage Forms; Directorate for the Quality of Medicines of the Council ofEurope: Germany 2009.55PHARMACEUTICAL ANALYSIS / QUALITY ASSURANCE / REGULATORY AFFAIRS poster presentationsFIFTH CONGRESS OF PHARMACY OF MACEDONIA WITH INTERNATIONAL PARTICIPATIONMacedonian Pharmaceutical Bulletin 57 (suppl), 2011rpm RSD after 5 min (%)50rpm 22.3375rpm 2.90Dissolution testEnd pointReleased active componentafter 30 minutes (%)50 rpm 80.7875 rpm 91.41100 rpm 96.36250 rpm 100.08*ISPITUVANjE NA KhIDRODINAMIChKITEEFEKTI VRZ TESTOT ZA DISOLUTsIJA NABCS KLASA II AKTIVNA KOMPONENTAFORMULIRANA KAKO TsVRSTA DOZAZhNAFORMA SO BRZO OSLOBODUVANjEIrena Brashnarska, Natasha Karalija, SuzanMemed-Sejfulakh, Sanja Simeonovska, GjorgjiPetrushevski, Ema Kikovska-Stojanovska, BiljanaShapkareva, Sonja UgarkovikjIstrazhuvanje i razvoj, ALKALOID AD, Aleksandar Makedonski 12,1000 Skopje, Republika MakedonijaVOVEDIn vitro testot za disolutsija vo poslednite dekadi vo razvojot nanovi proizvodi se izdvoi kako znachajna fizichko-khemiska alatka zaodreduvanje na farmatsevtskiot kvalitet i predviduvanje nabioraspo lozhlivosta na proizvodot. Razvojot na metodata zadisolutsija pretstavuva kontinuiran protses koj mora da gi pratipromenite kako shto se menuva proizvodot. Spetsifichniinformatsii za lekovitata supstantsa kako nejzinata rastvorlivost,pKa, stabilnosta kako funktsija od pH i BCS klasata go vodatistrazhuvachkiot tim kon razvoj na diskriminatoren metod zadisolutsija, spetsifichen za sekoj proizvod. Razlichni brzini narotatsija, razlichni mediumi i razlichni aparati za disolutsijatreba da se evaluiraat za da se definira metod za disolutsija kojkje dade vistinska slika za performansite na proizvodot, noistotaka kje ima dovolna diskriminatorna mokj da gi detektirapromenite vo formulatsijata. Evaluirani bea film oblozheni tableti so brzo osloboduvanje soaktivna komponenta od BCS Class II (niska rastvorlivost, visokapermeabilnost) i pKa vrednost od ~ 4.5 [1]. Aktivnata komponentataima pH zavisna rastvorlivost i porastot na pH ja podobruvanejzinata rastvorlivost, a so toa i brzinata na disolutsija,posebno koga pH > pKa na komponentata. Rastvorlivosta nalekovitata supstantsa e odredena so shake-flask metoda vo trirazlichni mediumi. Dobieni se slednive vrednosti 0.00385mg/ml,0.0113mg/ml i 0.143mg/ml za pH 2.2, pH 4.5 i pH 6.8, soodvetno.Aktivnata komponenta e tselosno jonizirana i brzo rastvorliva vointestinalniot region so pH ~6.5. Sledstveno, izborot nafosfaten pufer pH 6.8 [2] kako medium za disolutsija pretstavuvafizioloshki izbran medium, vo sklad so regulatornite baranja.Slika 1. Disolutsioni profili od mediumi so razlichno pHMETODI I MATERIJALIKvantifikatsija na protsentot na oslobodena aktivna komponentabeshe napravena so HPLC metoda so UV detektsija na 246 nm,instrument VWR Hitachi Elite LaChrom. Separatsijata e izvedena naRP Select B 125 x 4.0mm 5mm kolona. Testot za disolutsija eizveduvan na Varian VK 7025 tester za disolutsija so Apparatus I(basket) i Apparatus II (paddle). Odbrani vremenski tochki zadisolutsioni profili se 5, 10, 15, 30 i 45 minuti, dodeka za test vokrajna tochka e odbrana 30-tata minuta. Bo eksperimentalni tselikoristeni se kvantitativno proportsi-onalno formulirani film-oblozheni tableti so razlichna dozazhna jachina, proizvedeni so istproizvoden protses. REZULTATI I DISKUSIJAa) Vlijanie na brzina na vrtezhiSo variranje na brzinata na vrtezhi se evaluira efektot odkhidrodinamikata na brzinata na osloboduvanje na aktivnatakomponenta od formulatsijata. Evaluatsija na vlijanieto narazlichnite brzini na rotatsija beshe izvedena so testovi vo krajnatochka so 50 rpm, 75 rpm i 100 rpm. Brzinata od 50 rpm rezultirasheso formiranje na kupa, koe vodi kon netselosno osloboduvanje naaktivnata komponenta od tabletite. Dopolnitelno beshezabelezhana pregolema varija bilnost vo prvata vremenska tochkaod profilot so 50 rpm sporedeno so 75 rpm. Slika 2.